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Abstract Lung tumors are characterized by their high
metastatic potential, which is the main cause of therapeutic
failure. However, the exact cellular origin of metastasis
remains unknown. Since the introduction of the cancer
stem cell theory, lung cancer stem cells (LCSCs) have been
thought to represent metastasis-founding cells. The current
study aimed to evaluate whether LCSCs could be found in
the circulation. Expression of the stem cell markers CD133
and EpCAM was confirmed in tumor and normal lung
tissue by flow cytometry. Then, this technique was further
used to investigate the expression of CD133 and EpCAM
in the peripheral blood of 41 patients with primary lung
cancer. Putative LCSCs (CD133?EpCAM?) were present
in 6/7 tumor samples, and CD133?EpCAM? cells were
identified in the blood samples of 15 patients at a median
level of 40/ml of blood. EpCAM? cells were detected in
60 % of the patients, and the number of these cells was
higher in patients with adenocarcinoma than patients with
squamous cell carcinoma and was also higher in patients
with less advanced disease. Moreover, the frequency of this
subpopulation significantly correlated with the circulating
level of SSEA-4? cells. Additionally, CD133?EpCAM-
cells were found in 87 % of the patients, and the numbers
of these cells were significantly higher in patients with
distant metastases and correlated with disease stage. This
study confirmed the presence of an LCSC subpopulation
with a CD133?EpCAM? phenotype in the tumors and
blood of patients with lung cancer, and these results sug-
gest an important role for CD133 and EpCAM in lung
cancer progression and their potential application as novel
biomarkers of the disease.
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Introduction
Lung cancer is an aggressive, malignant neoplasm with
approximately 1.3 million new cases worldwide each year,
and poor prognoses lead to high levels of mortality among
men and women. However, 5-year survival rates greater
than 15 % are now being reported (Jemal et al. 2010). Two
main histological types of lung cancer can be identified:
non-small cell lung carcinoma (NSCLC) and small cell
lung carcinoma (SCLC), which is highly aggressive and
responsive to chemotherapy. Adenocarcinoma, an NSCLC
subtype, was recently shown to be the most frequently
observed type of lung cancer and is a candidate for targeted
therapy (Alberg et al. 2007). The low 5-year survival rate
for patients with lung cancer is related to the occurrence of
early, widespread metastases (including those to the bone
marrow, bones, brain, liver, and pleural cavity) and a high
rate of relapse, regardless of whether initial treatment led to
remission (Krzakowski 2010).
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Since the introduction of the cancer stem cell (CSC)
hypothesis in relation to acute myelogenous leukemia
(Lapidot et al. 1994), there is a growing body of evidence
to suggest that cancer development and resistance are dri-
ven by a rare subpopulation of cells with the ability to self-
renew and generate the broad heterogeneity of the primary
tumor mass following xenotransplantation into immuno-
deficient mice (Clevers 2011). Such CSCs have been found
and characterized in many solid tumors, including breast,
brain, colon, pancreatic and lung tumors (Al-Hajj et al.
2003; Eramo et al. 2008; Li et al. 2007; Ricci-Vitiani et al.
2007; Singh et al. 2003). Lung cancer stem cells (LCSCs)
were originally isolated using the CD133 antigen (promi-
nin-1), which is a common stem cell marker with an
unknown biological function. Lung cancer cells expressing
CD133 were found to be more resistant to chemothera-
peutics and form tumors when injected into SCID mice in
low numbers (Eramo et al. 2008). Other studies revealed
that these cells express the embryonic transcription factor
Oct-3/4, which is essential for maintenance of unique stem-
like properties (Chen et al. 2008). Another stem cell marker
is stage-specific embryonic antigen-4 (SSEA-4), which is
an embryonic stem cell surface protein that is lost during
differentiation (Draper et al. 2002).
Metastases originate from circulating tumor cells
(CTCs) that migrate through the blood and lymph. Circu-
lating lung cancer cells have been detected using various
methods, such as polymerase chain reaction (PCR) and
immunocytochemistry (Tsavellas et al. 2002). Moreover,
lung cancer cells have been identified in the blood based on
their expression of cytokeratin or epithelial cell adhesion
molecule (EpCAM/CD326) (Krebs et al. 2011). More
recently, circulating cancer cells were shown to express a
chemokine receptor for stromal derived factor-1 (SDF-1),
which is the CXCR4 receptor. It has also been suggested
that cells expressing CXCR4 may undergo chemotaxis
toward gradients of SDF-1 and therefore anchor at sites
rich in SDF-1 (e.g., bone marrow) to form metastases
(Reckamp et al. 2009). Although most cancer cells express
CXCR4, not all are able to form tumors (Eramo et al.
2008), and it is likely that not all of these cells are capable
of forming metastases.
Taken together, these observations encouraged us to
investigate whether cells with an LCSC phenotype could
be found in the peripheral blood of patients with lung
cancer. We first confirmed the presence of CD133?Ep-
CAM? cells in freshly obtained tumor tissue and then
sought to identify cells of this phenotype in the periph-
eral blood of patients with lung cancer. We also aimed to
determine whether the identification of circulating stem
cells could be correlated with various clinical data and
patient disease stage. For these purposes, flow cytometry
and staining using monoclonal antibodies targeting the




Tumor samples were obtained from patients with lung
cancer who had undergone elective tumor surgical resec-
tion (N = 7). Normal lung tissue specimens were obtained
from the same patients. These sections were resected from
macroscopically healthy lung parenchyma in the marginal
zone. All patients were primary cancer patients and
received no anticancer treatment prior to surgery.
Blood samples were obtained from patients who were
admitted to the Department of Pneumonology of the
Medical University of Warsaw and who had been diag-
nosed with lung cancer (N = 41). These patients did not
receive anticancer treatment prior to blood sample collec-
tion. Blood was also collected from patients in addition to
those who provided tumor samples.
Samples of peripheral blood were also collected from 15
healthy volunteers who served as the control group.
Only patients with histologically/cytologically con-
firmed lung cancers were included in the study group.
Demographic data and data regarding the clinical stage of
the disease were collected. The actual TNM classification
of disease stage was used (Goldstraw 2009). All patients
underwent thoracic computed tomography (CT) scan,
bronchoscopy, and ultrasonography of the abdominal
organs. Lymph node involvement was evaluated based on
the CT scan results and, if indicated, endobronchial ultra-
sound-guided transbronchial needle aspiration (EBUS/
TBNA). Distal metastases were verified in symptomatic
patients by appropriate imaging methods. The patient
characteristics are described in Table 1. Most patients had
advanced-stage disease (60 % in stage IV) and half of the
patents had distant metastases at the time of diagnosis.
Patients provided informed consent to be included in
this study, which had been approved by the local ethics
committee.
Flow Cytometry
Due to our preliminary results (unpublished data) which
showed that EpCAM-positive cells could be found in the
peripheral blood of cancer patients, we decided not to use
any pre-enrichment steps which can produce bias by loss of
particular cells. One milliliter of peripheral blood was
obtained. A total of 50 ll of blood was stained using the
following murine antibodies: APC-conjugated anti-CD133
(Miltenyi Biotec, Bergisch Gladbach, Germany), FITC-
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conjugated anti-EpCAM, and PE-conjugated anti-SSEA4
(Beckton Dickinson, San Jose, CA, USA). Isotype control
antibodies (BD Sciences, San Jose, CA, USA) were used
for control staining. After 30 min of incubation at 20 C,
erythrocytes were lysed with BD lysing solution and
washed with 2 % newborn calf serum in physiological
buffer solutions (PBS). The cells were subsequently fixed
in 0.5 % paraformaldehyde.
Tumor specimens and normal lung tissues were placed
in 0.9 % NaCl and immediately transported to the labora-
tory. Samples were digested by incubation in 0.1 % type I
collagenase (Sigma Aldrich, USA) in PBS for 2 h at 37 C
and then filtered through 40-lm steel mesh. The cell sus-
pensions were then washed with PBS and resuspended in
PBS for staining. The antibody staining was performed in
the same manner as for the blood cells.
Antibody-stained samples were analyzed using a
FACSCanto II flow cytometer and FACSDiva software
(Becton-Dickinson, San Jose, CA, USA). As CTC are
expected to be very rare, we collected at least 50,000
mononuclear cells from each sample. The percentage of
positive cells was recorded, and the absolute number of
positive cells per 1 ml of blood was calculated using the total
white blood count. Events were collected from the lym-
phocyte gate on the FSC/SSC dot plot and read on a CD133?
versus EpCAM? dot plot. The gating strategy and staining of
a probe is presented in Figs. 1 and 2. Efforts were made to
analyze 500,000–1,000,000 events from each sample. The
flow cytometry blood cell analysis results are presented as
the proportion of cells, the value of which is independent of
the sample size, and as the absolute number of cells in 1 ml of
blood (as a derivative of white blood count).
Statistical Methods
Comparisons between two groups were performed using
the Whitney–Mann U test. Differences were considered
significant for p \ 0.05. The results are expressed as the
median and P25–P75 values. The relationships between the
data were examined using the Spearman’s rank correlation
coefficient. Correlations with R C 0.4 and p \ 0.05 were
considered significant. Calculations were performed using
Statistica 9.0 software.
Table 1 Clinical characteristics of patients with lung cancer whose
blood was analyzed for circulating cancer stem cells
N 41
Mean age (years) 67 (49–92)
Male/female 27/14
Smoking history (pack years) 36 ± 18 all patients were smokers
or ex-smokers
NSCLC 34
Squamous cell carcinoma 9
Adenocarcinoma 8





Lymph nodes? 28 (68 %)
Distal metastases? 23 (56 %)
NSCLC non-small cell lung cancer, SCLC small cell lung cancer
Fig. 1 An example of dot plots of cells obtained from a digested lung
tumor that was stained for CD133 and EpCAM expression. a Mor-
phological cytogram showing the gating strategy for the dispersed
tumor cells. b Of the gated cancer cells, 5.6 % expressed EpCAM
only (Q1) and 0.82 % were positive for both EpCAM and CD133
(Q2)




The median patient age was 60 years, and six out of seven
patients were male. Four of the tissue samples were from
cases of adenocarcinoma and three from cases of squamous
cell carcinoma. CD133? and EpCAM? cells were present
at a higher number in all of the analyzed tumors in com-
parison to normal lung tissues (Table 2). The differences
between normal and malignant tissues were not significant,
which was likely due to the few number of samples
Fig. 2 Dot plots for the representative peripheral blood immunocy-
tochemical analysis. a The expression of stem cell markers was
analyzed in the lymphocyte gate. b The blood from this patient
contained 0.0119 % EpCAM? cells (Q1), 0.0059 % CD133? cells
(Q4) and 0.0016 % CD133?EpCAM? cells (Q2). Plots c, d show the
results from two other patients who had 0.0018 and 0.0019 %
CD133?EpCAM? cells (Q2)
Table 2 Proportion of CD133? and EpCAM? cells in lung cancer and normal lung tissues
CD133?EpCAM- (%) CD133?EpCAM? (%) CD133-EpCAM? (%)
Lung tissue 0.008 (0.007–0.009) 0.037 (0.010–0.044) 2.750 (1.000–7.300)
Tumor tissue 0.040 (0.002–0.100) 0.1000 (0.01–0.390) 3.000 (0.900–24.000)
Fold change 5.0 2.7 1.09
Results are expressed as the median and P25–P75 values
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examined (N = 7). The rare double-positive CD133?Ep-
CAM? cell subset was also present in six of the seven
tumor samples at a 2.7 times higher proportion than in the
healthy lung tissue [median values 0.1 (0.01–0.39 %) and
0.037 (0.01–0.0443 %), respectively; p = 0.16].
Although the difference in the level of EpCAM? cells in
relation to tumor histopathology was not significant
(p = 0.19), we observed a trend toward higher numbers of
positive cells in cases of adenocarcinoma, and the median
value of EpCAM? cells was 24 % in adenocarcinoma vs.
1.5 % in squamous cell carcinoma.
Peripheral Blood
To evaluate the specificity of flow cytometry, blood
samples from 15 healthy subjects were analyzed.
CD133?EpCAM- cells were found in all samples as
expected (median: 0.0092 %), while CD133-EpCAM?
and CD133?EpCAM? cells were not detected in any
healthy donor (data not shown).
Cells expressing CD133 only were detected in 36
(87 %) patients, and cells that were only EpCAM-positive
were found in the blood of 25 (60 %) patients. The median
values of the proportion and absolute number of CD133?
and EpCAM? cells are presented in Table 3. We detected
double-positive CD133?EpCAM? cells in the blood of 15
(36 %) patients at a median frequency of 0.0004 %.
CD133?EpCAM- and CD133-EpCAM? cells were
found in NSCLC and in SCLC tissues in similar propor-
tions. However, the absolute number of CD133?EpCAM-
cells was higher in patients with SCLC than NSCLC (299
vs. 204 cells/ml, p = 0.19). We also found that the fraction
of CD133-EpCAM? cells varied between the histopa-
thological types of non-small cell lung cancer evaluated,
and this fraction was increased in the blood of patients with
adenocarcinoma as compared to squamous cell carcinoma
(0.0130 vs. 0.0027 %, p = 0.2; Fig. 3).
We next compared the proportion of analyzed cells
between patients with advanced disease (i.e., stages IIIB
and IV) and less advanced disease (i.e., stages I–IIIA), and
found that the proportion of CD133-EpCAM? cells was
significantly lower in the blood of patients with advanced
disease (0.0018 vs. 0.0067; p = 0.018). Additionally, the
number of CD133?EpCAM- cells per ml of blood varied
in relation to disease stage, and the highest number of
CD133?EpCAM- cells was found in the blood of patients
with stage IV disease (Fig. 4).
The proportion and absolute number of cells expressing
CD133 or EpCAM only and the combination of both
markers, detected in the blood of patients with lung cancer
in relation to distal metastases are shown in Table 3. We
found an elevated proportion and number of CD133? cells
in the blood of patients with metastatic disease, while cells
expressing EpCAM were significantly depleted in patients
with metastases (median value: 0.0015 vs. 0.0046 % in
patients without metastases; p = 0.012; Fig. 5). Interest-
ingly, the number of CD133?EpCAM? double-positive
cells per 1 ml of blood was higher in patients with meta-
static disease, although this result was observed in only
three patients.
Additionally, we observed the presence of SSEA-4?
cells in 67 % of the patients examined at a median
Table 3 Results from the analysis of CD133 and EpCAM expression in the peripheral blood of patients with lung cancer
All Metastases No metastases Fold change (meta vs. no meta)
CD133?EpCAM- (%) 0.0022 (0.0009–0.0036) 0.0021 (0.0011–0.0034) 0.0022 (0.0006–0.0039) 0.95
CD133?EpCAM- (per 1 ml) 204 (67–333) 247 (141–405) 138 (48–313) 1.80
CD133-EpCAM? (%) 0.0026 (0.0015–0.0063) 0.0015 (0.0004–0.0045) 0.0046 (0.0024–0.0075) 0.32
CD133-EpCAM? (per 1 ml) 260 (54–354) 138 (34–303) 298 (213–521) 0.46
CD133?EpCAM? (%) 0.0004 (0.0003–0.0008) 0.0004 (0.0002–0.0008) 0.0005 (0.0003–0.0008) 0.8
CD133?EpCAM? (per 1 ml) 40 (31–83) 49 (34–132) 39 (15–83) 1.26
Data are shown for all patients and grouped according to metastasis status. Results are expressed as the median and P25–P75 values or the
percentage of the total cell count
Fig. 3 Differences in the proportion of EpCAM? cells in the
peripheral blood of lung cancer patients according to tumor histopa-
thological type. SCC squamous cell carcinoma, AD adenocarcinoma.
Data are expressed as the median, P25–P75 of the peripheral blood
nuclear cells
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expression level of 0.00011 % (100/ml). Interestingly,
there was a significant correlation (p \ 0.05, R = 0.64)
between the percentage of SSEA-4? cells and the per-
centage of EpCAM? cells.
Discussion
The concept of CSCs has shed new light on tumor biology.
CSCs, which are thought to possess unique capacities such
as giving rise to an entire heterogeneous tumor mass and
surviving therapeutic regimens, are candidate metastasis-
initiating cells. Eramo et al. (2008) and Tirino et al. (2009)
identified a lung CSC subpopulation among CD133-
expressing cancer cells; moreover, these cells were shown
to be capable of generating tumor xenografts, acquiring
specific linear markers upon differentiation and escaping
chemotherapy-induced apoptosis. Because CSCs and
normal stem cells show similar trafficking abilities in
response to the CXCR4/SDF-1 axis (Kucia et al. 2005), we
hypothesized that lung CSCs would egress into the circu-
lation. This study sought to investigate whether these cells
could be found in the peripheral blood of patients with lung
cancer and therefore contribute to the development of
metastasis.
We first investigated whether cells with a putative LCSC
phenotype could be isolated from freshly obtained tumors.
To identify these cells, we chose to stain for the CD133 and
EpCAM molecules, as these double-positive cells were
previously shown to possess stem cell characteristics in
lung cancer (Eramo et al. 2008). The CD133 antigen is
commonly used to identify normal and CSCs, and anti-
EpCAM staining was performed in this study because this
molecule is often overexpressed in lung cancers, although
its functional role in forming metastases remains contro-
versial (van der Gun et al. 2010). We confirmed the
presence of CD133?EpCAM? cells in lung tumor tissues,
and these cells were also found in the normal lung paren-
chyma but at a much lower frequency. We also noted a
tendency toward higher EpCAM expression in cases of
adenocarcinoma as compared to squamous cell carcinoma,
which is consistent with previous data (Went et al. 2006).
The presence of CD133?EpCAM? cells in the normal
tissue and their higher number in the tumor suggest that
cells of such phenotype are important for the development
of cancer and these particular cells may be the target of
carcinogenesis, but this hypothesis needs further research.
However, we can explain this interesting result by the fact
that in ‘‘healthy’’ lung the process of carcinogenesis is also
possible, taking into account the individual genetic pre-
disposition and influence of environmental factors.
Immunohistochemical comparison of the CD133? cells on
normal and malignant tissue could be useful to clarify the
results obtained by flow cytometry. Also, the functional
assays were not the objective of this clinical observation
study.
To evaluate the presence of circulating CSCs, we uti-
lized flow cytometry. Although several techniques can be
used for the identification of circulating cancer cells, such
as PCR, microchips, enrichment and cytological evalua-
tion, flow cytometry was selected for the current study.
With flow cytometry, numerous parameters can be simul-
taneously recorded, including cell morphology, selected
marker expression, and marker co-expression. These
properties enable the exclusion of cellular debris, dead
cells and free circulating mRNA, which can generate
artifacts and false-positive errors. Taken together, the
analysis of surface protein expression using flow cytometry
has been shown to be a relevant method, as CTCs have
been detected in patients with lung cancer (based mostly on
cytokeratin expression) by numerous groups (Devriese
Fig. 4 Number of CD133?EpCAM- cells per ml of peripheral blood
from patients with lung cancer in relation to disease stage I, II, III or
IV. Data are expressed as the median, P25–P75
Fig. 5 Proportion of EpCAM-positive cells as the percentage of
peripheral blood nuclear cells count in patients with lung cancer with
or without distal metastases. Data are expressed as the median,
P25–P75
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et al. 2012; Reckamp et al. 2009). Although some CTC
pre-enrichment techniques (CellSearch, isolation by size of
epithelial tumor cells) are often used, we chose to apply
standard flow cytometry for our purpose. The choice of
flow cytometry was based on its advantages over PCR-
based methods, as it enables the colocalization of analyzed
markers on the single cell level. On the other hand, during
the pre-enrichment steps some cell subpopulations are lost,
which limits the variety of data obtained for analyses of
correlations. Our preliminary results revealed that Ep-
CAM-positive cells could be identified in the blood of
cancer patients with this method, while no EpCAM? or
CD133?EpCAM? cells could be found in healthy controls.
Also, flow cytometry proved its utility to enumerate CTC
in other tumors (Rao et al. 2005; Wang et al. 2012).
However, the current study is the first report in which
circulating LCSCs were analyzed. The same immunocy-
tochemical staining strategy was applied to tumor tissues,
and we phenotypically identified CD133?EpCAM? CSCs
in 36 % of the blood samples evaluated. Although most of
the patients studied were in an advanced disease stage,
CSCs were absent in only a few cases. This result is not
surprising, as circulating cancer cells were found in 46 %
of patients in a recent study by Devriese et al. (2012),
which suggests that circulating CSCs would be identified at
an even lower frequency. Additionally, we did not find any
relationship between disease stage and the presence and
number of CD133?EpCAM? cells. This finding may be
related to the limited number of patients and the few cases
of non-advanced cancer studied. Moreover, a study by
Theodoropoulos et al. (2010), which identified circulating
putative breast CSCs, also failed to find clinical correla-
tions with CSCs.
An additional significant finding of the current study
concerns the identification of circulating cells expressing
the EpCAM antigen alone. As mentioned previously, this
molecule is often overexpressed in lung cancers and has
been used to detect and enrich circulating cancer cells
(Devriese et al. 2012). CD133-EpCAM? cells were found
in the blood of more than half of the patients studied, and
we observed that the percentage of CD133-EpCAM? cells
in the peripheral blood varied according to histological
tumor type. Patients with adenocarcinoma had a higher
number of these cells than patients with squamous cell
carcinoma, and this finding corresponds to previous results
observed in tumor tissues (Baeuerle and Gires 2007; The-
odoropoulos et al. 2010; Went et al. 2006). To the best of
our knowledge, these differences in the circulating Ep-
CAM? cells in the context of tumor histopathology have
not been previously reported. Moreover, in our study
population, the proportion of EpCAM-positive cells was
higher in patients without distal metastases, which may
have some clinical implications. The significance of the
presence and identification of EpCAM in cancers depends
on the cancer type (van der Gun et al. 2010). In renal clear
cell carcinoma and thyroid carcinoma, EpCAM expression
has been correlated with improved survival, and in lung
cancer, EpCAM overexpression was also associated with
improved (Baeuerle and Gires 2007) or not worse prog-
nosis (Kim et al. 2009). The mechanism of action of this
molecule is pleiotropic, and EpCAM has been described as
a highly immunogenic tumor-associated antigen (Baeuerle
and Gires 2007). A possible explanation of this observation
is that the expression of EpCAM is related to more dif-
ferentiated status of CTCs.
SSEA-4 is an embryonic marker that, in adults, can be
found in primitive stem cells, such as small embryonic-like
stem cells (Kucia et al. 2007), or certain types of tumor
cells, as recently reported for epithelial ovarian carcinoma
(Ye et al. 2010). In our study, the proportion of SSEA-4-
positive cells correlated with cells expressing EpCAM.
However, a small number of cases were evaluated, and the
origin of the SSEA-4-positive circulating cells in patients
with lung cancer requires further study.
We also analyzed the CD133?EpCAM? cells in the
peripheral blood of patients with lung cancer. This sub-
population was found at various levels in almost all of the
samples examined. The absolute number of these cells was
higher in patients with distal metastases, and this number
positively correlated with the clinical lung cancer stage
(i.e., greatest number found among patients with stage IV
disease). The CD133 molecule is expressed by numerous
stem cells, although it is mostly expressed by hematopoi-
etic stem cells and endothelial progenitor cells in the
peripheral blood (Dome et al. 2006; Vroling et al. 2010).
An elevated number of endothelial progenitor cells
(CD133?CD34?VEGFR2?) in patients with lung cancer
have been previously reported, which was shown to cor-
relate with disease stage and clinical behavior (Dome et al.
2006). Recently, hematopoietic stem cells (identified as
CD133?CD34?CD45? cells) were also found in the
peripheral blood of patients with lung cancer, and their
number negatively correlated with time to progression
(Vroling et al. 2010). According to these studies, we would
predict that CD133? cells are adult stem cells and mostly
hematopoietic and endothelial in nature. Therefore, the
current study identified the potential utility of measuring
CD133 expression as a potential biomarker in patients with
cancer.
The results of our study seem to corroborate the cancer
stem cell theory and the presence maturation continuum
among both normal and cancer cells. Primitive progenitor
cells expressing CD133 and EpCAM proteins are rare, but
they expand in lung cancer compared to the healthy lung.
Cells expressing EpCAM antigen only have differentiated
phenotype and their frequency is almost equal in the
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normal and malignant tissue. Analysis of peripheral blood
led us to a similar conclusion, as CTCs of patients without
distal metastases had differentiated CD133-EpCAM-
phenotype.
Aside from several strengths, our study had some limi-
tations. First, we used only one technique to analyze
putative CSCs and, therefore, further research is warranted.
The blood volume used in our study is low, but we still
managed to identify EpCAM and CD133-positive cells and
clinical differences correlating to their frequencies. Addi-
tionally, this study did not find any significant correlation
between the number of circulating CD133?EpCAM? cells
and the clinical data. One potential reason for this incon-
clusive result may have been the limited number of cases
studied. Unfortunately, we were unable to study and ana-
lyze stem cell markers in tumors and blood from the same
patients. Additionally, the patient group included NSCLC
and SCLC patients, and most of these individuals had been
diagnosed with advanced disease.
In conclusion, this study confirmed the existence of
CD133?EpCAM? cells in lung tumor tissues and, for the
first time, identified these cells in the peripheral blood of
patients with lung cancer. Additionally, we demonstrated
that the number of circulating EpCAM-positive cells
varied depending on the lung tumor type and the presence
of distal metastases. Cells expressing the CD133 antigen
alone, which are likely hematopoietic and endothelial
progenitors, were shown to correlate with the lung cancer
stage and could potentially be useful as a biomarker of
tumor spread.
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